LENZ Therapeutics LENZ
NASDAQ LENZ
$3.22 +0.03 (+0.94%)
As of: Oct 21, 2026 · 3:59 PM EDT

LENZ Therapeutics (LENZ) Current Deferred Revenue (2026)

Updated

LENZ Therapeutics (LENZ) posted Current Deferred Revenue of $785,000 for Q2 2026.

Analysis

LENZ Therapeutics (LENZ) Current Deferred Revenue (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 LENZ Therapeutics 101.65 Mn -871.25 Mn 5.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 785,000.00
API Access

LENZ Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=LENZ&period=max&api_key=YOUR_API_KEY